NO2721243T3 - - Google Patents

Info

Publication number
NO2721243T3
NO2721243T3 NO12801069A NO12801069A NO2721243T3 NO 2721243 T3 NO2721243 T3 NO 2721243T3 NO 12801069 A NO12801069 A NO 12801069A NO 12801069 A NO12801069 A NO 12801069A NO 2721243 T3 NO2721243 T3 NO 2721243T3
Authority
NO
Norway
Application number
NO12801069A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2721243T3 publication Critical patent/NO2721243T3/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41621,2-Diazoles condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61Halogen atoms or nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/34One oxygen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO12801069A 2014-10-01 2012-06-14 NO2721243T3 (he)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462058316P 2014-10-01 2014-10-01

Publications (1)

Publication Number Publication Date
NO2721243T3 true NO2721243T3 (he) 2018-10-20

Family

ID=53784023

Family Applications (1)

Application Number Title Priority Date Filing Date
NO12801069A NO2721243T3 (he) 2014-10-01 2012-06-14

Country Status (33)

Country Link
EP (4) EP3089979B1 (he)
JP (4) JP6462865B2 (he)
KR (2) KR101921436B1 (he)
CN (3) CN114957255A (he)
AR (1) AR101367A1 (he)
AU (3) AU2015324530B2 (he)
CA (1) CA2963395C (he)
CL (1) CL2017000712A1 (he)
CO (1) CO2017003833A2 (he)
CY (2) CY1119678T1 (he)
DK (2) DK3293186T3 (he)
EA (1) EA031590B1 (he)
ES (3) ES2655884T3 (he)
HR (2) HRP20171950T1 (he)
HU (2) HUE052812T2 (he)
IL (2) IL251434B (he)
LT (2) LT3089979T (he)
MA (1) MA40123A1 (he)
MX (2) MX2017003695A (he)
MY (1) MY183987A (he)
NO (1) NO2721243T3 (he)
PE (2) PE20210922A1 (he)
PH (2) PH12017500580A1 (he)
PL (1) PL3089979T3 (he)
PT (2) PT3293186T (he)
RS (2) RS56786B1 (he)
SG (2) SG11201702576QA (he)
SI (2) SI3089979T1 (he)
TN (2) TN2017000112A1 (he)
TW (3) TWI692478B (he)
UY (1) UY36244A (he)
WO (1) WO2016053455A1 (he)
ZA (1) ZA201702478B (he)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
NO2760821T3 (he) 2014-01-31 2018-03-10
CN110845498B (zh) * 2014-01-31 2023-02-17 百时美施贵宝公司 作为因子xia抑制剂的具有杂环p2′基团的大环化合物
WO2016036893A1 (en) 2014-09-04 2016-03-10 Bristol-Myers Squibb Company Diamide macrocycles that are fxia inhibitors
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
ES2761774T3 (es) 2014-10-01 2020-05-21 Merck Patent Gmbh Derivados del ácido borónico
NO2721243T3 (he) * 2014-10-01 2018-10-20
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JP6742348B2 (ja) 2015-06-19 2020-08-19 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company 第xia因子阻害剤としてのジアミド大員環
ES2871111T3 (es) 2015-07-29 2021-10-28 Bristol Myers Squibb Co Inhibidores macrocíclicos del factor XIa que contienen un grupo P2' no aromático
CN107849026B (zh) * 2015-07-29 2021-01-01 百时美施贵宝公司 携带烷基或环烷基p2′部分的因子xia大环抑制剂
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
US10752641B2 (en) 2016-03-02 2020-08-25 Bristol-Myers Squibb Company Diamide macrocycles having factor XIa inhibiting activity
CR20180496A (es) 2016-03-31 2018-12-06 Univ Leuven Kath Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
WO2017167950A1 (en) 2016-03-31 2017-10-05 Janssen Pharmaceuticals, Inc. Substituted indole derivatives as dengue viral replication inhibitors
US10730884B2 (en) 2016-04-01 2020-08-04 Janssen Pharmaceuticals, Inc. Substituted indole compound derivatives as dengue viral replication inhibitors
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
CN110062757B (zh) * 2017-01-18 2022-03-04 广东东阳光药业有限公司 凝血因子XIa抑制剂及其用途
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
BR112019024311A2 (pt) 2017-05-22 2020-07-28 Janssen Pharmaceuticals, Inc. derivados de indolina substituídos como inibidores da replicação viral do dengue
WO2018215315A1 (en) 2017-05-22 2018-11-29 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors
CN114375290A (zh) * 2019-04-11 2022-04-19 百时美施贵宝公司 制备(6r,10s)-10-{4-[5-氯-2-(4-氯-1h-1,2,3-三唑-1-基)苯基]-6-氧代基-1(6h)-嘧啶基}-1-(二氧甲基)-6-甲基-1,4,7,8,9,10-六氢-11,15-(亚甲桥基)吡唑并[4,3-b][1,7]二氮杂环十四炔-5(6h)-酮的新颖合成选项
BR112021020257A2 (pt) * 2019-04-11 2021-12-07 Bristol Myers Squibb Co Desempenho intensificado de sólido amorfo e formulações solubilizadas para realizar concentrações de plasma terapêutico
KR102709654B1 (ko) * 2019-04-16 2024-09-26 차이나 리소어시즈 바이오파마슈티컬 컴퍼니 리미티드 XIa 인자 억제제로서의 거대고리 유도체
JP7286001B2 (ja) * 2019-07-23 2023-06-02 メッドシャイン ディスカバリー インコーポレイテッド 第XIa因子阻害剤としての大環状誘導体
BR112022005660A2 (pt) * 2019-09-27 2022-07-12 Shenzhen Salubris Pharm Co Ltd Inibidores de fxia e método de preparação dos mesmos e uso farmacêutico dos mesmos.
BR112022020243A2 (pt) * 2020-04-10 2022-11-22 Bristol Myers Squibb Co Formas cristalinas de (9r,13s)-13-{4-[5-cloro-2-(4-cloro-1h-1,2,3-triazol-1-il)fenil]-6-oxo-1,6-diidropirimidin-1-il}-3-(difluorometil)-9-metil-3,4,7,15-tetraazatriclo[12,3,1,02,6]octadeca-1(18),2(6),4,14,16-pentaen-8-ona
TW202229280A (zh) * 2020-10-12 2022-08-01 美商必治妥美雅史谷比公司 (6r,10s)-10-{4-[5-氯-2-(4-氯-1h-1,2,3-三唑-1-基)苯基]-6-側氧基-1(6h)-嘧啶基}-1-(二氟甲基)-6-甲基-1,4,7,8,9,10-六氫-11,15-(亞甲橋基)吡唑并[4,3-b][1,7]二氮雜環十四炔-5(6h)-酮之製備方法
KR20230142724A (ko) 2021-01-08 2023-10-11 브리스톨-마이어스 스큅 컴퍼니 인자 XIa 억제제에 대한 항체 및 항원 결합 펩티드및 그의 용도
TW202246268A (zh) * 2021-04-21 2022-12-01 大陸商上海美悦生物科技發展有限公司 FXIa抑制劑及其藥物組合物、製備方法和用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0028489B1 (en) 1979-11-05 1983-10-05 Beecham Group Plc Enzyme derivatives, and their preparation
PE121699A1 (es) 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
ZA985247B (en) 1997-06-19 1999-12-17 Du Pont Merck Pharma Guanidine mimics as factor Xa inhibitors.
CA2383008A1 (en) 1999-06-14 2000-12-21 Amanda Jane Lyons Compounds
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
AR035216A1 (es) 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
RS20080517A (en) 2001-09-21 2009-07-15 Bristol-Myers Squibb Company, Lactam containing compounds and derivatives thereof as factor xa inhibitors
US20040180855A1 (en) 2003-02-19 2004-09-16 Schumacher William A. Methods of treating thrombosis with reduced risk of increased bleeding times
JP5841547B2 (ja) * 2010-02-11 2016-01-13 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company 第xia因子阻害剤としてのマクロ環
TW201311689A (zh) * 2011-08-05 2013-03-16 必治妥美雅史谷比公司 作為因子xia抑制劑之新穎巨環化合物
TW201319068A (zh) 2011-08-05 2013-05-16 必治妥美雅史谷比公司 作為xia因子抑制劑之環狀p1接合劑
US9327839B2 (en) * 2011-08-05 2016-05-03 General Atomics Method and apparatus for inhibiting formation of and/or removing ice from aircraft components
SG11201403402VA (en) * 2011-12-21 2015-01-29 Ono Pharmaceutical Co Compounds
PL2880026T3 (pl) * 2012-08-03 2017-08-31 Bristol-Myers Squibb Company Dihydropirydon P1 jako inhibitory czynnika XIA
HUE031582T2 (en) 2012-08-03 2017-07-28 Bristol Myers Squibb Co Dihydropyridone as xia factor inhibitors
NO2760821T3 (he) * 2014-01-31 2018-03-10
CN110845498B (zh) * 2014-01-31 2023-02-17 百时美施贵宝公司 作为因子xia抑制剂的具有杂环p2′基团的大环化合物
NO2721243T3 (he) * 2014-10-01 2018-10-20

Also Published As

Publication number Publication date
IL251434B (he) 2020-08-31
CO2017003833A2 (es) 2017-07-11
EP3089979A1 (en) 2016-11-09
BR112017006702A2 (pt) 2017-12-26
KR20170057431A (ko) 2017-05-24
HUE052812T2 (hu) 2021-05-28
AU2021245098B2 (en) 2023-11-23
TN2018000229A1 (en) 2019-10-04
MA40123A1 (fr) 2017-09-29
ES2836270T3 (es) 2021-06-24
SG11201702576QA (en) 2017-04-27
CN110734435A (zh) 2020-01-31
PH12020500195A1 (en) 2021-02-08
CY1123663T1 (el) 2022-03-24
TW202043228A (zh) 2020-12-01
UY36244A (es) 2016-01-29
CN110734435B (zh) 2022-06-07
EP3828186A3 (en) 2021-07-28
TWI692478B (zh) 2020-05-01
KR20180126612A (ko) 2018-11-27
EP3828186A2 (en) 2021-06-02
EP4286372A3 (en) 2024-02-21
EP3089979B1 (en) 2017-10-18
SI3293186T1 (sl) 2021-01-29
ZA201702478B (en) 2019-06-26
PT3089979T (pt) 2018-01-16
JP2019069989A (ja) 2019-05-09
JP7317905B2 (ja) 2023-07-31
AR101367A1 (es) 2016-12-14
PT3293186T (pt) 2020-12-09
EP3293186A1 (en) 2018-03-14
MY183987A (en) 2021-03-17
TWI769442B (zh) 2022-07-01
HUE038061T2 (hu) 2018-09-28
NZ731416A (en) 2024-01-26
ES2963267T3 (es) 2024-03-26
AU2015324530A1 (en) 2017-05-18
AU2020200376A1 (en) 2020-02-06
CN106795161A (zh) 2017-05-31
PE20170939A1 (es) 2017-07-13
JP6462865B2 (ja) 2019-01-30
HRP20171950T1 (hr) 2018-02-23
CY1119678T1 (el) 2018-04-04
MX2020010840A (es) 2020-11-06
NZ766570A (en) 2024-01-26
SI3089979T1 (sl) 2017-12-29
CA2963395A1 (en) 2016-04-07
JP2023134734A (ja) 2023-09-27
TWI834182B (zh) 2024-03-01
PE20210922A1 (es) 2021-05-19
RS61183B1 (sr) 2021-01-29
ES2655884T3 (es) 2018-02-22
TW201613923A (en) 2016-04-16
AU2020200376B2 (en) 2021-07-08
AU2021245098A1 (en) 2021-10-28
PH12017500580B1 (en) 2017-08-30
IL251434A0 (he) 2017-05-29
TW202310844A (zh) 2023-03-16
DK3089979T3 (en) 2018-01-15
WO2016053455A1 (en) 2016-04-07
EP3293186B1 (en) 2020-09-23
CL2017000712A1 (es) 2017-11-03
PL3089979T3 (pl) 2018-02-28
JP6937734B2 (ja) 2021-09-22
TN2017000112A1 (en) 2018-07-04
PH12017500580A1 (en) 2017-08-30
KR102269999B1 (ko) 2021-06-25
HRP20201927T1 (hr) 2021-02-05
IL276470A (he) 2020-09-30
IL276470B (he) 2021-04-29
KR101921436B1 (ko) 2018-11-22
LT3293186T (lt) 2020-12-28
EA201790595A1 (ru) 2017-07-31
JP2021185182A (ja) 2021-12-09
EP4286372A2 (en) 2023-12-06
MX2017003695A (es) 2017-05-30
SG10201911652TA (en) 2020-02-27
CA2963395C (en) 2023-03-14
CN106795161B (zh) 2019-10-15
RS56786B1 (sr) 2018-04-30
JP2017530157A (ja) 2017-10-12
DK3293186T3 (da) 2020-12-14
CN114957255A (zh) 2022-08-30
EA031590B1 (ru) 2019-01-31
LT3089979T (lt) 2017-12-27
EP3828186B1 (en) 2023-08-23
AU2015324530B2 (en) 2019-10-24

Similar Documents

Publication Publication Date Title
BR112014023320A2 (he)
BR112014023806A2 (he)
BR112014017635A2 (he)
BR112014017614A2 (he)
BR112014020010A2 (he)
BR112014017625A2 (he)
BR112014017659A2 (he)
BR112014017744A2 (he)
BR112014017646A2 (he)
NO2721243T3 (he)
BR112014017638A2 (he)
BR112014017607A2 (he)
BR112014024049A2 (he)
BR112014017634A2 (he)
BR112014017609A2 (he)
BR112014017644A2 (he)
BR112014017647A2 (he)
BR112014017618A2 (he)
BR112014017630A2 (he)
BR112014017652A2 (he)
BR112014017621A2 (he)
BR112014017622A2 (he)
BR112014017627A2 (he)
BR112014017623A2 (he)
BR112014017631A2 (he)